Abstract:The pathological processes leading to synapse loss, neuronal loss, brain atrophy and gliosis in Alzheimer's disease (AD) and their relation to vascular disease and immunological changes are yet to be fully explored. Amyloid-β (Aβ) aggregation, vascular damage and altered immune response interact at the blood-brain barrier (BBB), affecting the brain endothelium and fuelling neurodegeneration. The aim of the present systematic literature review was to critically appraise and to summarise the published evidence on the clinical correlations and pathophysiological concepts of BBB damage in AD, focusing on human data. The PubMed, Cochrane, Medline and Embase databases were searched for original research articles, systematic reviews and meta-analyses, published in English language from 01/2000 to 07/2021, using the keywords Alzheimer*, amyloid-β or β-amyloid or abeta and BBB. This review shows that specific changes of intercellular structures, reduced expression of transendothelial carriers, induction of vasoactive mediators and activation of both astroglia and monocytes/macrophages characterise BBB damage in human AD and AD models. BBB dysfunction on magnetic resonance imaging takes place early in the disease course in AD-specific brain regions. The toxic effects of Aβ and apolipoprotein E (ApoE) are likely to induce a non-cerebral-amyloid-angiopathy-related degeneration of endothelial cells, independently of cerebrovascular disease; however, some of the observed structural changes may just arise with age. Small vessel disease, ApoE, loss of pericytes, proinflammatory signalling and cerebral amyloid angiopathy enhance BBB damage. Novel therapeutic approaches for AD, including magnetic resonance-guided focused ultrasound, aim to open the BBB, potentially leading to an improved drainage of Aβ along perivascular channels and increased elimination from the brain. In vitro treatments with ApoE-modifying agents yielded promising effects on modulating BBB function. Reducing cardiovascular risk factors represents one of the most promising interventions for dementia prevention at present. However, further research is needed to elucidate the connection of BBB damage and tau pathology, the role of proinflammatory mediators in draining macromolecules and cells from the cerebral parenchyma, including their contribution to cerebral amyloid angiopathy. Improved insight into these pathomechanisms may allow to shed light on the role of Aβ deposition as a primary versus a secondary event in the complex pathogenesis of AD.

Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

β-amyloid's neurotoxic mechanisms as defined by in vitro microelectrode arrays: a review

The Amyloid-β Pathway in Alzheimer's Disease

Aß Pathology and Neuron–Glia Interactions: A Synaptocentric View

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

Targeting the Synapse in Alzheimer’s Disease

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

Amyloid-beta and tau protein beyond Alzheimer’s disease

Neuronal networks with coupling through amyloid beta: towards a theory for Alzheimer's disease

Physiological Roles of beta-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology

A review of proposed mechanisms for neurodegenerative disease

Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity

Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons

The duality of amyloid-β: its role in normal and Alzheimer's disease states

Targeting synapse function and loss for treatment of neurodegenerative diseases

Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis

N-Methyl-<i>D</i>-Aspartate Receptors Mediate Excitotoxicity in Amyloid Beta-Induced Synaptic Pathology of Alzheimer’s Disease